» Articles » PMID: 31182092

Host-microbe Interactions in the Pathogenesis and Clinical Course of Sarcoidosis

Overview
Journal J Biomed Sci
Publisher Biomed Central
Specialty Biology
Date 2019 Jun 12
PMID 31182092
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Sarcoidosis is a rare inflammatory disease characterized by the development of granulomas in various organs, especially in the lungs and lymph nodes. Clinics of the disease largely depends on the organ involved and may range from mild symptoms to life threatening manifestations. Over the last two decades, significant advances in the diagnosis, clinical assessment and treatment of sarcoidosis have been achieved, however, the precise etiology of this disease remains unknown. Current evidence suggests that, in genetically predisposed individuals, an excessive immune response to unknown antigen/s is crucial for the development of sarcoidosis. Epidemiological and microbiological studies suggest that, at least in a fraction of patients, microbes or their products may trigger the immune response leading to sarcoid granuloma formation. In this article, we discuss the scientific evidence on the interaction of microbes with immune cells that may be implicated in the immunopathogenesis of sarcoidosis, and highlight recent studies exploring potential implications of human microbiota in the pathogenesis and the clinical course of sarcoidosis.

Citing Articles

HLA genotyping in cardiac and other extrapulmonary manifestations of sarcoidosis.

Senay E, Korkmaz C, Zamani A, Zamani A, Demirbas S, Yildirim M Medicine (Baltimore). 2025; 104(9):e41640.

PMID: 40020105 PMC: 11875599. DOI: 10.1097/MD.0000000000041640.


Retrotrans-genomics identifies aberrant THE1B endogenous retrovirus fusion transcripts in the pathogenesis of sarcoidosis.

Funaguma S, Iida A, Saito Y, Tanboon J, De Los Reyes F, Sonehara K Nat Commun. 2025; 16(1):1318.

PMID: 39920152 PMC: 11805910. DOI: 10.1038/s41467-025-56567-6.


Sarcoidosis: molecular mechanisms and therapeutic strategies.

Xu D, Tao X, Fan Y, Teng Y Mol Biomed. 2025; 6(1):6.

PMID: 39904950 PMC: 11794924. DOI: 10.1186/s43556-025-00244-z.


Chronic Sarcoidosis: Diagnostic Difficulties and Search for New Criteria of Inflammatory Activity (A Case Report and Literature Review).

Starshinova A, Berg E, Rubinstein A, Kulpina A, Kudryavtsev I, Kudlay D J Clin Med. 2024; 13(22).

PMID: 39598118 PMC: 11594891. DOI: 10.3390/jcm13226974.


Linking Microbiota Profiles to Disease Characterization in Common Variable Immunodeficiency: The Case of Granulomatous-Lymphocytic Interstitial Lung Disease.

Cabanero-Navalon M, Carda-Dieguez M, Moral Moral P, Mira A, Balastegui-Martin H, Salavert-Lleti M Biomedicines. 2024; 12(10).

PMID: 39457552 PMC: 11505043. DOI: 10.3390/biomedicines12102239.


References
1.
Toutous-Trellu L, Ninet B, Rohner P, Auckenthaler R, Saurat J, Pechere M . Three cases of cutaneous sarcoidosis: search for bacterial agent by the 16S RNA gene analysis and treatment with antibiotics. Dermatology. 2000; 200(4):342-5. DOI: 10.1159/000018406. View

2.
Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L . The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001; 137(1):69-73. DOI: 10.1001/archderm.137.1.69. View

3.
Eishi Y, Suga M, Ishige I, Kobayashi D, Yamada T, Takemura T . Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol. 2002; 40(1):198-204. PMC: 120089. DOI: 10.1128/JCM.40.1.198-204.2002. View

4.
Litinsky I, Elkayam O, Flusser G, Segal R, Yaron M, Caspi D . Sarcoidosis: TB or not TB?. Ann Rheum Dis. 2002; 61(5):385-6. PMC: 1754100. DOI: 10.1136/ard.61.5.385. View

5.
Eklund A . Aetiology, pathogenesis and treatment of sarcoidosis. J Intern Med. 2003; 253(1):2-3. DOI: 10.1046/j.1365-2796.2003.01072.x. View